The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.

Abstract

BACKGROUND:

Two COX isoenzymes are known, COX-1 and COX-2, for which the main inhibitors are the NSAIDs. The common anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes. The COX-2 inhibitors represent a new class of drugs that do not affect COX-1 but selectively block COX-2. This selective action provides the benefits of reducing inflammation without irritating the stomach and cardiovascular effects.

OBJECTIVE:

This review focuses on patents published in the field during 2002 - 2008, paying particular attention to promising COX-2 inhibitors.

CONCLUSION:

Structural analogues of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole and thione derivatives emerge as promising leads for the treatment of inflammation, pain and other diseases.

• Authors: Teodorico C Ramalho, Marcus V J Rocha, Elaine F F da Cunha, Matheus P Freitas
• Journal: Expert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 19 Issue 9 Pg. 1193-228 (Sep 2009) ISSN: 1744-7674 [Electronic] England
• PMID: 19563267 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Analgesics
• Cyclooxygenase 2 Inhibitors
• Cyclooxygenase 2

Topics

• Analgesics (adverse effects, pharmacology)
• Animals
• Cyclooxygenase 2 (drug effects, metabolism)
• Cyclooxygenase 2 Inhibitors (adverse effects, pharmacology)
• Drug Delivery Systems
• Humans
• Inflammation (drug therapy, physiopathology)
• Pain (drug therapy, physiopathology)
• Patents as Topic